“…PCSK9, independent of its enzymatic activity, induces the low‐density lipoprotein receptor (LDLR) degradation in the liver, resulting in increasing in the circulating LDL‐C (cholesterol) levels (Della Badia, Elshourbagy, & Mousa, ; Seidah, Abifadel, Prost, Boileau, & Prat, ; Soutar, ). Therefore, PCSK9 has been increasingly appreciated to play a key role in atherosclerosis (Huynh, ; Li & Li, ; Seidah, Awan, Chretien, & Mbikay, ; Whayne, ). Although an increase in blood LDL‐C by PCSK9 is important in atherogenesis, many studies suggest that PCSK9 accelerates atherosclerosis through mechanisms that are beyond its effects on LDL‐C levels (Cariou, Ding, & Mehta, ; Denis et al, ; Shapiro & Fazio, ; Tavori et al, ).…”